Latest Industry Insights

In this interview, we spoke with Knut Wintergerst, PhD, General Manager of Biomolecular Systems and Solutions (BSS) and Diagnostics and Genomics Group (DGG) at Agilent to learn more about why DNA and RNA sample integrity is important to scientists and how it can be maintained and analyzed.

By studying gene expression modifications induced by the immune response, Novigenix has developed a blood test for colorectal cancer. This Q&A with Jan Groen, CEO, provides insights on the test, and on the field of study that could revolutionize cancer diagnosis.

We recently spoke to Richard Brand, CFO and Dhruvajyoti Roy, Director of Technology from the Laboratory for Advanced Medicine (LAM) to learn more about how LAM is developing methylation-based tests for the early detection and intervention of cancer.

Given that bad antibodies are likely to blame for a significant proportion of the reproducibility crisis in science, any efforts to reduce batch-to-batch variability are more than welcome. One company with a plan to help in this area is “Absolute Antibody”, who believe that recombinant antibodies are the way forward. To learn more about making antibodies with recombinant technology, we spoke to Ian Wilkinson, PhD, Chief Scientific Officer.

The development of GMCTs has been halted by issues surrounding the most critical step in their creation, the introduction of new genetic material. Recently, Indee Labs announced the publication of a study illustrating the efficacy of it's GMCT development and manufacturing technology. We spoke with Indee Labs' CEO Ryan Pawell to learn more about the technology and its applications.

We recently spoke to Charlie Silver, CEO and Co-Founder of Mission Bio, to learn more about how they are helping researchers profile mutational heterogeneity at the single-cell level.

DNAfit is a personalized health and wellness company that offers an array of nutritional profiling services based on genetic science and technology. We spoke with Avi Lasarow, CEO and founder of DNAFit, to learn more about why it is important to look at our genetics in relation to diet and exercise choices, and what research currently exists in the field.

This year’s Advances in Genome Biology and Technology meeting showcased some of the most exciting developments in genomic technology. We caught up with Twist Bioscience CEO Emily Leproust to discuss the importance of target enrichment in next generation sequencing and the advancements in the field that caught her eye at AGBT.

Despite the great excitement about exosomes and their huge diagnostic and therapeutic potential, the technology needed to advance this work is lacking. We spoke to Jim West, CEO of Clara Biotech, who tells us how his team is working to fill that gap.

Major advances have occurred in the fields of proteomics and genomics over recent years. Now, scientists are utilizing the technologies from each approach collectively in a novel research area named proteogenomics. We spoke with Alexzander Asea, Professor and Director at Precision Therapeutics Proteogenomics Diagnostics Center, University of Toledo, to learn more about the applications of proteogenomics in precision medicine.